10-Q: Elevance Health Q3 2026: Revenue Up, Net Income Mixed

Elevance Health reported a 0.7% increase in Q3 operating revenue to $50.44 billion, driven by premium rate hikes and CarelonRx growth, while net income saw a 14.8% rise to $1.365 billion.

Summary

• Elevance Health's Q3 2026 operating revenue reached $50.44 billion, a 0.7% increase year-over-year, driven by premium rate adjustments in Health Benefits and growth in CarelonRx.
• Shareholders' net income for Q3 2026 was $1.365 billion, a 14.8% increase from Q3 2025, attributed to higher investment income and lower amortization expenses.
• For the nine-month period, shareholders' net income decreased by 10.2% to $4.592 billion, impacted by a loss contingency accrual for Medicare Advantage risk adjustment data and a decrease in Health Benefits operating gain.
• Total medical membership slightly declined by 1.1% to 44.88 million members, primarily due to Medicaid redeterminations and decreases in Medicare Advantage and FEP.
• The company maintained a strong liquidity position with $39.057 billion in cash, cash equivalents, and investments as of September 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting a stable financial performance with some areas of growth, though tempered by ongoing challenges in specific segments and regulatory uncertainties.

Positives

• Operating revenue increased by 0.7% to $50.44 billion for the three months ended September 30, 2026.
• Shareholders' net income for the three months ended September 30, 2026 increased by 14.8% to $1.365 billion.
• Diluted EPS for the three months ended September 30, 2026 rose by 17.9% to $6.27.
• Net investment income increased significantly by 65.9% for the three months and 47.3% for the nine months, driven by higher income from alternative investments.
• Commercial Fee-Based business saw a 2.2% increase in membership.
• Vision membership increased by 9.7%.

Negatives

• Total medical membership decreased by 1.1% to 44.88 million members as of September 30, 2026.
• Medicaid membership declined by 4.9%, and Medicare Advantage membership decreased by 15.5%.
• Shareholders' net income for the nine months ended September 30, 2026 decreased by 10.2% to $4.592 billion.
• Diluted EPS for the nine months ended September 30, 2026 decreased by 7.3% to $21.01.
• Operating gain for the Health Benefits segment decreased by 27.5% for the three months and 20.3% for the nine months.
• The company recorded a $593 million accrual related to Medicare Advantage risk adjustment data resubmission.

Risks

• Trends in healthcare costs and utilization rates.
• Reduced enrollment in key government programs like Medicare and Medicaid.
• Changes in federal, state, and international laws and regulations impacting healthcare and insurance.
• Cyber-attacks or data security incidents.
• Failure to effectively maintain and modernize information systems.
• Negative changes in economic and market conditions affecting liquidity and investment portfolios.
• Intense competition and the ability to adapt to industry changes.
• Risks associated with Medicare and Medicaid program compliance and Star Ratings.

Future Outlook

The company expects to fund future operations, commitments, and strategic transactions through operating cash flows, existing cash and investments, and potential financing sources. The company believes its liquidity will be adequate for the next twelve months.

Management Comments

• The company is working on program improvements in partnership with states, strengthening care and provider network management, optimizing clinical strategy, and enhancing payment integrity to manage costs.
• The company strives to price health benefit products consistent with anticipated underlying medical cost trends and makes frequent adjustments to respond to legislative and regulatory changes.
• Elevance Health is expanding its operations into select service areas in Florida, Maryland, and Texas through its Simply Healthcare and Wellpoint brands.
• The company is expanding offerings focused on net client cost and leveraging clinical programs, specialty pharmacy, and home-delivery capabilities.
• The company intends to continue to vigorously defend ongoing litigation, believing these cases are without merit.

Industry Context

StockSavvy.ai notes that Elevance Health's performance reflects broader industry trends, including rising medical costs, shifts in membership between government and commercial plans, and increasing focus on integrated healthcare services and pharmacy benefit management.

Comparison to Industry Standards

• The benefit expense ratio of 90.6% for Q3 2026 is slightly lower than the prior year's 91.3%, indicating improved cost management relative to premiums, which is a key metric in the health insurance industry.
• The operating expense ratio of 11.4% for Q3 2026 is higher than the prior year's 10.5%, suggesting increased investment in technology and regulatory compliance, a trend seen across the industry.
• The company's Medicare Advantage Star Ratings (49% of members in plans rated 4.0 stars or higher for 2027 payments) are a critical benchmark for performance and reimbursement in the Medicare Advantage market.
• The decline in Medicaid membership due to redeterminations is a widespread issue affecting many health insurers operating in this segment.

Legal Proceedings

• Elevance Health is a defendant in the consolidated In re Blue Cross Blue Shield Antitrust Litigation, with ongoing follow-on cases from opted-out parties.
• The company is defending against a civil lawsuit filed by the DOJ concerning Medicare risk adjustment data submissions under the False Claims Act.
• Independent Dispute Resolution (IDR) matters under the No Surprises Act are being evaluated and liabilities recorded where probable and estimable.
• A federal securities class action lawsuit alleges false and misleading statements regarding the Company's 2024 earnings guidance.
• Three related derivative lawsuits have been filed against directors and officers in connection with the securities class action.

Related Party Transactions

• Transactions with Mosaic Health included care delivery and enablement services, amounting to $197 million and $583 million for the three and nine months ended September 30, 2026, respectively.
• Transactions with Liberty Dental included administrative services for Medicare Advantage members, amounting to $126 million and $382 million for the three and nine months ended September 30, 2026, respectively.

Stakeholder Impact

• Shareholders: Net income for the quarter increased, but year-to-date net income decreased, impacting EPS.
• Members: Membership declined slightly, with notable decreases in Medicaid and Medicare Advantage, potentially affecting access to services.
• Providers: Ongoing litigation and regulatory matters, including antitrust cases and IDR disputes, could impact provider reimbursement and relationships.
• Employees: The Operating Model Transformation Program includes workforce reductions and role realignments.

Next Steps

• Continue to implement the 2026-2027 Operating Model Transformation Program.
• Monitor and adapt to evolving regulatory guidance and potential legislative changes.
• Focus on managing medical cost trends through various medical management programs.
• Continue to expand CarelonRx offerings and capabilities.
• Manage membership shifts and their impact on profitability.

Key Dates

Recommendation

The filing indicates a mixed financial performance. While Q3 showed revenue and net income growth driven by premium increases and investment income, the year-to-date decline in net income, coupled with membership attrition and significant legal/regulatory risks, warrants a cautious approach. The company's ability to manage rising medical costs and navigate regulatory changes will be key. Therefore, a 'hold' recommendation is appropriate, pending further clarity on these challenges.

Keywords

health insurance, managed care, Medicare, Medicaid, pharmacy services, healthcare services, premium revenue, medical claims